The incidence of oxcarbazepine-associated Stevens-Johnson syndrome is estimated to range between 0.5-6 cases/million per year. If you' re one of those cases, then there is a 100% chance you' ll be fighting this rare and potentially life-threatening hypersensitivity reaction involving the skin and mucous membranes.
Review results from a study that explore the severity of psoriasis, dermatology-related quality of life, and psychiatric health of the patients with reference to sociodemographic, lifestyle, and clinical characteristics.
Did you know that about 1 in 3 patients in dermatology settings has psychiatric comorbidity? To explore the awareness, knowledge, practicing patterns, and attitudes of dermatologists toward psychocutaneous disorders, the authors of this study conducted a survey in Turkey. This questionnaire-based study included 115 dermatologists.
Psychogenic purpura is a rare condition characterized by spontaneous development of painful edematous skin lesions progressing to ecchymosis over the next 24 hours. Severe stress and emotional trauma always precede the skin lesions. This report provides an overview of psychogenic purpura and presents the case of a 15-year-old girl.Â
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”